CHASE WILLIAM J 4

What Happened William J. Chase, a director of Intellia Therapeutics (NTLA), was granted two awards on June 9, 2026: 9,200 restricted stock units (RSUs) and a derivative award covering 13,300 shares (an option-type grant). Both were reported as acquisitions at $0.00 per share (no cash paid at grant). The RSUs represent a contingent right to receive one share of common stock per unit (see footnote F1). The derivative award vests in full on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders (footnote F2).

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (appears timely).
• Grants: 9,200 RSUs (acquired at $0.00) and 13,300-share derivative/option grant (acquired at $0.00).
• Purchase/sale price: $0.00 (typical for equity compensation awards).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 explains RSUs convert 1:1 to common shares when settled; F2 describes vesting (earlier of one-year anniversary or next annual meeting).
• No 10b5-1 plan, tax-withholding, cashless sale, or late-filing flags noted in the supplied details.

Context These are compensation-related grants (awards), not open-market purchases or sales. Grants like RSUs and option awards are common for board compensation and do not by themselves signal a director buying or selling stock. The economic value of these awards depends on Intellia’s future stock price and any additional plan terms not included in the excerpt.